secwatch.observer — SEC 8-K summary
======================================

Issuer:     GeneDx Holdings Corp. (WGS)
CIK:        0001818331
Form:       8-K
Filed at:   2024-04-29T23:59:59+00:00
Accession:  0001818331-24-000021
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GeneDx Q1 exome/genome revenue up 96% YoY; raises FY 2024 guidance to $235-245M
-------------------------------------------------------------------------------

- Revenue from continuing ops $61.5M (+51% YoY); exome/genome revenue $44.0M (+96% YoY).
- Adjusted gross margin expanded to 61% from 34% YoY; exome/genome margin above 65%.
- Adjusted net loss narrowed to $8.5M (83% YoY improvement); GAAP net loss $20.2M.
- Cash burn reduced 71% YoY to $17.2M; cash position $113.9M as of March 31.
- Raised FY 2024 revenue guidance to $235-245M; reiterate path to profitability in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818331/000181833124000021/0001818331-24-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818331/000181833124000021/wgs-20240429.htm
  HTML page:      https://secwatch.observer/filing/0001818331-24-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer